Phase II randomized study of Abiraterone acetate plus ADT versus ARN 509 versus Abiraterone and ARN 509 in patients with advanced prostate cancer with non-castrate testosterone levels.
Fernando Maluf, Oren Smaletz, Fabio Schutz, Vinicius Carrera Souza, Andre Poisl Fay, Daniel Herchenhorn, Gustavo Werutsky, Telma Murias Santos
ASCO GU 2018
Full link: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.TPS404#affiliationsContainer